Payment overview · 2025
General Payments
$192.33
12 reported records · 2 companies
Healthcare provider profile · identity verified
Terry Allen Knepshield, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · COWANSVILLE, PA · NPI 1205894144
Verified facts
What the public records show
CMS Open Payments records show Terry Allen Knepshield, PAC received $192.33 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 90.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.91 | 90.9% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.42 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.33 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $174.91 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
401 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 128 |
| Lisinopril | Lisinopril | 545 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 108 |
| Omeprazole | Omeprazole | 508 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 472 | 88 |
| Simvastatin | Simvastatin | 446 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 438 | 112 |
| Ozempic | Semaglutide | 401 | 54 |
| Potassium Chloride | Potassium Chloride | 395 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 71 |
| Alprazolam | Alprazolam | 339 | 56 |
| Gabapentin | Gabapentin | 335 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 60 |
| Furosemide | Furosemide | 250 | 54 |
| Losartan Potassium | Losartan Potassium | 239 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 51 |
| Montelukast Sodium | Montelukast Sodium | 224 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 222 | 47 |
| Metformin Hcl Er | Metformin Hcl | 219 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 48 |
| Alendronate Sodium | Alendronate Sodium | 207 | 37 |
| Metformin Hcl | Metformin Hcl | 192 | 43 |
| Repaglinide | Repaglinide | 175 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 29 |
| Prednisone | Prednisone | 166 | 85 |
| Finasteride | Finasteride | 149 | 32 |
| Tramadol Hcl | Tramadol Hcl | 141 | 34 |
| Ezetimibe | Ezetimibe | 138 | 31 |
| Azithromycin | Azithromycin | 131 | 93 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 23 |
| Eliquis | Apixaban | 130 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 39 |
| Allopurinol | Allopurinol | 118 | 26 |
| Lorazepam | Lorazepam | 118 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 24 |
| Trazodone Hcl | Trazodone Hcl | 113 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 18 |
| Carvedilol | Carvedilol | 105 | 15 |
| Celecoxib | Celecoxib | 100 | 23 |
| Synthroid | Levothyroxine Sodium | 93 | 21 |
| Meloxicam | Meloxicam | 90 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 19 |
| Sertraline Hcl | Sertraline Hcl | 89 | 18 |
| Clonazepam | Clonazepam | 84 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 26 |
| Ibuprofen | Ibuprofen | 83 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 18 |
| Januvia | Sitagliptin Phosphate | 76 | 18 |
| Amoxicillin | Amoxicillin | 74 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 67 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 67 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 55 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 11 |
| Tradjenta | Linagliptin | 62 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 15 |
| Fenofibrate | Fenofibrate | 60 | suppressed |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 47 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 13 |
| Glimepiride | Glimepiride | 56 | 13 |
| Spironolactone | Spironolactone | 55 | suppressed |
| Baclofen | Baclofen | 54 | 12 |
| Mirtazapine | Mirtazapine | 54 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 54 | 14 |
| Fluconazole | Fluconazole | 53 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Valsartan | Valsartan | 52 | suppressed |
| Atenolol | Atenolol | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 21 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 11 |
| Jardiance | Empagliflozin | 49 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 48 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 26 |
| Ketoconazole | Ketoconazole | 40 | 19 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Carisoprodol | Carisoprodol | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 25 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Desoximetasone | Desoximetasone | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 12 |
| Indomethacin | Indomethacin | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Insupen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.33 · 12 records | Novo Nordisk Inc | REXULTI, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error